Oncoscience

Biological role of miR-204 and miR-211 in melanoma

Marianna Vitiello1,2, Romina D’Aurizio3, Laura Poliseno1,2

1Oncogenomics Unit, CRL-ISPRO, 56124 Pisa, Italy

2Institute of Clinical Physiology, CNR, 56124 Pisa, Italy

3Institute of Informatics and Telematics, CNR, 56124 Pisa, Italy

Correspondence to:

Laura Poliseno, email:laura.poliseno@gmail.com

Marianna Vitiello, email:mvitiello@ifc.cnr.it

Keywords: melanoma, small RNA-seq, BRAF inhibitors, miR-204, miR-211

Received: March 28, 2018 Accepted: May 18, 2018 Published: August 22, 2018

Abstract

In this short report, we pinpoint some technical and conceptual flaws that we found in the article entitled “miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma” (Díaz-Martínez et al., Cancer Research 2018). We also discuss how, in our opinion, these flaws led Díaz-Martínez and colleagues to incorrect conclusions about the biological role that miR-204 and miR-211 play in melanoma and about the terms of their involvement in the phenomenon of resistance to BRAF inhibitors.


PII: 443